top of page

In addition to presenting data at ESMO positioning its PD1 as potentially the standard of care in a new indication, Incyte thinks it has an important new drug in its CDK2 inhibitor

Sep 14, 2024
1 min read

CEO Hervé Hoppenot describes the strategy for Incyte's PD1, and developing the CDK2 for ovarian and endometrial cancers, and possibly beyond.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page